Aims of the study
=================

In our intensive care unit, the ventilator-associated pneumonia coefficient and density of incidence were respectively 21 for 100 ventilated-patients, and 20 for 1000 days of ventilation. In 1995, we had observed an increase of ceftazidime-resistant *Pseudomonas aeruginosa* frequency. We, therefore, compared the ecology and the cost of antibiotherapy between the first 1995 semester and the first 1996 semester, after we prescribed less of ceftazidime, and we limited the probabilist treatment in only at risk patients.

Patients and methods
====================

For suspicion of ventilator-associated pneumonia in patients presenting the criteria of Andrews we realized 75 bronchiolo-alveolar lavages in the first 1995 semester (GI) and 70 in the first 1996 semester (G2). The diagnosis of this pneumonia was positive when bacteriologic quantitative cultures were \> 10^4^ cfu/ml.

Results
=======

See table.

Between the two periods the total cost of antibiotherapy and the cost of beta-lactamins respectively decreased to 15 and 25%.

Conclusion
==========

Our strategy was favourable for ecology and economy in our intensive care unit. These results must be confirmed during the 2 complete years.

  \%           *Ps*   *Ps*   *Acinetobacter*   KES    *Staph*
  ------------ ------ ------ ----------------- ------ ---------
  **G1**                                              
   Incidence   19     16.7   6                 14.3   19
   CTZ-S       61     85     0                 90     \-
   AMK-S       55     0      40                83     \-
   CPX-S       50     0      0                 83     \-
   OXA-S       \-     \-     \-                \-     30
  **G2**                                              
   Incidence   13     11.5   3                 23     \-
   CTZ-S       85     100    33                94     \-
   AMK-S       80     0      33                94     \-
   CPX-S       40     0      0                 88     \-
   OXA-S       \-     \-     \-                \-     63

*Ps, Pseudomonas;* KES, *Klebsiella-Enterobacter-Serratia; Staph, Staphyloccocus;* CTZ-S, ceftazidime-sensitive; AMK-S, amikacin-sensitive; CPX-S, ciprofloxacin-sensitive; OXA-S, oxacillin-sensitive.
